CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The CARBALIVE project explores a novel nanoporous carbon material to treat fatty liver disease and cirrhosis. It aims to evaluate its safety and efficacy in clinical trials, potentially offering a cost-effective solution for managing chronic liver conditions.
Chronic liver disease affects about 29-million Europeans accounting for about 170,000 deaths at a cost of around €15.8bn.
This chronic non-communicable disease is increasing at an alarming rate due to increasing European obesity, alcohol use and ageing.
The three main causes of the disease; alcohol, fatty liver and viral hepatitis are amenable to prevention and treatment.
Gut-derived endotoxins and bacterial translocation are central factors implicated in the pathogenesis of fatty liver disease…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, Basingstoke
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Spain, Madrid
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: No
United Kingdom, Brighton
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
United Kingdom, NEWMARKET
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
